Recruiting Lung Cancer Studies in Anaheim
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatmen...
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and ...
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy ...
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cel...
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with a...
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first s...
About Lung Cancer Clinical Trials in Anaheim
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 6 lung cancer clinical trials recruiting participants in Anaheim, CA. These studies are seeking a combined 2,883 participants. Research is being sponsored by AstraZeneca, Mirati Therapeutics Inc., SWOG Cancer Research Network. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Anaheim — FAQ
Are there lung cancer clinical trials in Anaheim?
Yes, there are 6 lung cancer clinical trials currently recruiting in Anaheim, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Anaheim?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Anaheim research site will contact you about next steps.
Are clinical trials in Anaheim free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Anaheim studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 6 active trials in Anaheim are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov